« Back
Home /
Cabozantinib

Cabozantinib

€49.00

Excl. VAT

Item no.	HY-13016-5mg
Manufacturer	MedChem Express
CASRN	849217-68-1
Amount	5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Breast Cancer Heart & Blood Cancer
Type	Inhibitors
Clone	N/A
Specific against	other
Purity	99.96
Formula	C28H24FN3O5
Citations	Acta Pharmacol Sin. 2021 Jan;42(1):108-114. Adv Healthc Mater. 2023 Aug 21;e2302046. Am J Reprod Immunol. 2021 Mar;85(3):e13352. Antioxidants (Basel). 2021, 10(9), 1336. Biochem Biophys Rep. 2020 Jan 17;21:100726. Biomaterials. 16 September 2022. Biomed Chromatogr. 2020 Aug;34(8):e4862. Biomed Chromatogr. 2023 May 15;e5685. Biomedicines. 2020 Nov 28;8(12):547. bioRxiv. 2023 Apr 14. Cancer Discov. 2021 Jan;11(1):126-141. Cancer Lett. 2019 Apr 10;447:105-114. Cancers (Basel). 2024 Jan 8, 16(2), 269. Drug Des Devel Ther. 2018 Apr 30;12:1009-1017. Eur J Drug Metab Pharmacokinet. 2021 Jul 18;1-11. Exp Cell Res. 2020 Aug 1;393(1):112054. Front Oncol. 2022 Jul 7;12:915319. Fundam Clin Pharmacol. 2021 Feb 1. Int J Mol Sci. 2022 Sep 14;23(18):10677. Invest Ophthalmol Vis Sci. 2022 Dec 1;63(13):14. J Cell Biochem. 2020 Mar;121(3):2343-2353. J Med Chem. 2016 Jan 14;59(1):358-73. J Neurosci. 2020 Dec 9;40(50):9602-9616. J Pharm Anal. 2021 Jun 19. J Transl Med. 2023 Jan 9;21(1):9. Mediat Inflamm. 2020 Oct 24;2020:1649453. Mol Cancer Res. 2019 Feb;17(2):499-507. Mol Cancer Ther. 2017 Nov;16(11):2387-2398. Patent. US20170349880A1. Patent. US20220332731A1. PLoS One. 2017 Sep 25;12(9):e0185321. React Kinet Mech Cat. 07 January 2022. Saudi Pharm J. 2023 Aug 24, 101756. Sci Rep. 2019 Nov 12;9(1):16600. Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. Spectrochim Acta A Mol Biomol Spectrosc. 2016 Apr 15;159:199-208. Harvard Medical School LINCS LIBRARY Virology. 2023 Jun 21. [1]Fuse MA, et al. Combination Therapy With c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells. Mol Cancer Ther. Mol Cancer Ther. 2017 Nov;16(11):2387-2398. [2]You WK, et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res, 2011, 71(14), 4758-4768. [3]Yakes FM, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther, 2011, 10(12), 2298-2308.
Smiles	O=C(C1(CC1)C(NC2=CC=C(F)C=C2)=O)NC3=CC=C(C=C3)OC4=C5C=C(OC)C(OC)=CC5=NC=C4
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	XL184; BMS-907351
Available
Product Description	Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC50 values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis[1][2].
StorageTemperature	4°C (Powder, protect from light)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
Molecular Weight	501.51
Clinical Information	Launched
Solubility	DMSO : 25 mg/mL (ultrasonic)\|H2O : 1 mg/mL (ultrasonic; warming; heat to 60°C)
Isoform	Met; VEGFR1/Flt-1; VEGFR2/KDR/Flk-1; VEGFR3/Flt-4
Pathway	Apoptosis; Protein Tyrosine Kinase/RTK
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-13016-5mg-safety-datasheet.pdf